We are excited to announce the recent publication of a protocol paper for the EpiCom (Epilepsy Comorbidities) study, a multicenter, open-label, phase 3b/4 study, designed in collaboration with patient advisory groups and healthcare professionals. The study is investigating the impact of adjunctive cannabidiol (CBD) treatment on TAND in individuals with TSC-associated seizures.